SUPPLEMENTARY MATERIAL

Table 6 Internal CINV prevention and control guidelines for chemotherapy with high emetogenic potential Day 1 Day 2 Day 3 Day 4 Day 5 Before After After chemotherapy Chemotherapy Anticipatory

CINV*

1 – 2 mg Acute CINV Delayed CINV aprepitant aprepitant

125 mg 80 mg 80 mg dexamethasone dexamethasone dexamethasone dexamethasone dexamethasone 8 – 12 mg 4 mg 4 mg 4 mg 4 mg 4 mg 1 mg or orondansetron 8 mg Breakthrough CINV* metoclopramide metoclopramide metoclopramide metoclopramide 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or

thiethylperazine thiethylperazine thiethylperazine thiethylperazine thiethylperazine 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg CINV, chemotherapy-induced nausea and vomiting. *, as needed. breakthrough CINV, CINV that occurs despite the use of therapy.

Table 7 Internal CINV prevention and control guidelines for chemotherapy with moderate emetogenic potential Day 1 Day 2 Day 3 Day 4 Day 5 Before After After chemotherapy Chemotherapy Anticipatory

cinv* lorazepam

1 – 2 mg Acute CINV Delayed CINV aprepitant aprepitant aprepitant

125 mg** 80 mg** 80 mg** dexamethasone dexamethasone dexamethasone dexamethasone dexamethasone

8 – 20 mg 4 mg 4 mg 4 mg 4 mg granisetron 1 mg or 8 mg Breakthrough CINV* metoclopramide metoclopramide metoclopramide metoclopramide metoclopramide 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or

thiethylperazine thiethylperazine thiethylperazine thiethylperazine thiethylperazine 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg CINV, chemotherapy-induced nausea and vomiting. *, as needed. **, recommendeed for patients with additional risk factors for CINV.

Table 8 Internal CINV prevention and control guidelines for chemotherapy with low emetogenic potential Day 1 Day 2 Day 3 Day 4 Day 5 Before After After chemotherapy Chemotherapy Anticipatory

cinv* lorazepam

1 – 2 mg Acute CINV Delayed/ breakthrough CINV* dexamethasone dexamethasone dexamethasone dexamethasone dexamethasone

4 – 12 mg 4 mg 4 mg 4 mg 4 mg alternative: metoclopramide metoclopramide metoclopramide metoclopramide metoclopramide 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or thiethylperazine 6.5 – 19.5 mg thiethylperazine thiethylperazine thiethylperazine thiethylperazine 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg CINV, chemotherapy-induced nausea and vomiting. *, as needed.

Table 9 Internal CINV prevention and control guidelines for chemotherapy with minimal emetogenic potential Day 1 Day 2 Day 3 Day 4 Day 5 Before After After chemotherapy Chemotherapy Anticipatory

CINV* lorazepam

1 – 2 mg Acute CINV* Delayed/ breakthrough CINV* metoclopramide metoclopramide metoclopramide metoclopramide metoclopramide 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or 10 – 40 mg or / thiethylperazine thiethylperazine thiethylperazine thiethylperazine thiethylperazine 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg 6.5 – 19.5 mg CINV, chemotherapy-induced nausea and vomiting. *, as needed.

Table 10 Level of nausea and number of emetic episodes in the acute and the delayed phase – data from patients' questionnaires Level of nausea Acute phase; n(%) Delayed phse; n(%) 0 39 (62.9) 35 (56.5) 1 1 (1.6) 1 (1.6) 2 6 (9.7) 4 (6.5) 3 3 (4.8) 9 (14.5) 3.5 0 1 (1.6) 4 1 (1.6) 1 (1.6) 5 8 (12.9) 7 (11.3) 6 1 (1.6) 4 (6.5) 7 2 (3.2) 0 9 1 (1.6) 0 Number of emetic episodes Acute phase; n(%) Delayed phase; n(%) 0 59 (95.2) 58 (93.5) 2 1 (1.6) 3 (4.8) 4 1 (1.6) 1 (1.6) 6 1 (1.6) 0 Level of nausea, marked value on 10-point Visual Analogue Scale.

Table 11 Received combinations of in the study Combination of antiemetics Number of patients Percentage (%) of patients no antiemetic therapy 11 17.7 dexamethasone 16 25.8 dexamethasone, granisetron 9 14.5 dexamethasone, granisetron, diazepam 18 29.0 dexamethasone, granisetron, aprepitant 8 12.9 All 62 100